Table 1. Demographic and clinical data.
| No. (%) | |
|---|---|
| Male sex |
137 (61) |
| Median age (range) |
62 (31–84) |
|
Liver metastases | |
|
No. of tumours | |
| 1 | 66 (30) |
| 2 | 45 (20) |
| ⩾3 |
112 (50) |
| Median maximum size (range), cm |
2.9 (0.1–17) |
| Initially unresectable |
83 (37) |
| Synchronous |
72 (32) |
| Bilobar location |
132 (59) |
| Preoperative portal vein embolization |
55 (24) |
|
Preoperative chemotherapy | |
| Median no. of preoperative cycles | 6 (3–34) |
| 5-FU oxaliplatin | 70 (31) |
| 5-FU irinotecan | 34 (15) |
| 5-FU oxaliplatin+bevacizumab | 33 (15) |
| 5-FU oxaliplatin+cetuximab | 17 (8) |
| 5-FU irinotecan+bevacizumab | 50 (22) |
| 5-FU irinotecan+cetuximab |
19 (8) |
|
Outcome | |
| Median follow-up, months | 47 (3–106) |
| 5-year overall survival | 59% |
Abbreviation: FU=fluorouracil.